Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 safety study of OSU6162 for mental fatigue and wakefulness disturbances in neurological disorders
2013-002545-10Phase 2Completed
- Sponsor
- Carlsson Research
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OSU-6162 in cognitive fatigue and Excessive Daytime Sleepiness (EDS), sponsored by Carlsson Research. Primary endpoint: Safety of OSU6162. Started Nov 2013; status: completed.
02
Drugs
OSU-6162
03
Conditions
cognitive fatigueExcessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on 2013-002545-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002545-10.